Arcus biosciences stock.

Nov 7, 2023 · Arcus Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 32 million compared to USD 33 million a year ago. FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score …Dec 9, 2021 · Shares of the cancer specialist Arcus Biosciences ( RCUS -1.07%) jumped by approximately 31% during the month of November, according to data from S&P Global Market Intelligence. The biotech's ... A high-level overview of Arcus Biosciences, Inc. (RCUS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …

Concurrent with the May 2020 collaboration agreement, Gilead and Arcus entered into a stock purchase agreement under which Gilead made a $200 million equity investment in Arcus. That stock ...In the last 3 months, 9 analysts have offered 12-month price targets for Arcus Biosciences. The company has an average price target of $46.33 with a high of $70.00 and a low of $23.00. Below is a ...

Jarrett Jennifer, the Chief Operating Officer of Arcus Biosciences Inc, sale 45,000 shares at $20.25 during a trade that took place back on Jul 28, which means that Jarrett Jennifer is holding 336,566 shares at $911,250 based on the most recent closing price. Stock Fundamentals for RCUS. Current profitability levels for the company are sitting at:

– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – Exelixis, Inc. (Nasdaq: EXEL) and Arcus Biosciences (NYSE: RCUS) today …15 мая 2023 г. ... Gilead is paying $35 million cash to expand an existing oncology partnership with Arcus Biosciences into inflammatory diseases.Arcus Biosciences, Inc. (RCUS) closed the last trading session at $28.63, gaining 12.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Arcus Biosciences (RCUS - Research Report), with a pr...

$14.19 Previous Close- YTD Change -29.93% 12 Month Change -46.94% Day Range14.19 - 14.81 52 Wk Range12.95 - 36.13 Volume 540.58K (63.44% of Avg) 65 Day Avg: 852.17K …

Oct 31, 2023 · Arcus Biosciences, Inc. Appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...

Get the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing. See the current price, performance outlook, earnings date, dividend yield, fair value and more.Investigating Combination Therapies to Treat Cancer. Learn how cancer biology is guiding the study of potential, new combination medicines to treat specific types of cancer. Arcus is a biopharmaceutical company aiming to bring together scientists, physicians & advisors to focus on developing best-in-class cancer therapies.If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Discover historical prices for RCUS stock on Yahoo Finance. View daily, weekly or monthly format back to when Arcus Biosciences, Inc. stock was issued. ... Arcus Biosciences, Inc. (RCUS) NYSE ... Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, ... 2023, and restricted stock units to acquire a total of 6,300 shares of the Company’s common stock.

Selection of optimized drug candidates, dosing regimen, pharmacodynamic endpoints, tumor types, and biomarkers for translating inhibition of the adenosine pathway into effective anti-tumor activity. The molecules and their uses are investigational. Arcus has not received approval from any regulatory authority for any use globally, and the ...Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit. Arcus is evaluating zimberelimab in combination with multiple molecules within the Arcus portfolio, including several registrational Phase 3 ...Is Arcus Biosciences (NYSE:RCUS) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, pricing and company ...Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic …In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Arcus Biosciences (RCUS – Research Report), with a price target of $51.00.The company’s shares ...HAYWARD, Calif., January 10, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...Nov 29, 2023 · Powered By Q4 Inc. 5.111.2.6. See updates on stock information on the Arcus Biosciences site and contact Investor Relations here.

Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently down 4.32% so far this month. During the month of August, Arcus Biosciences Inc’s stock price has reached a high of $19.72 and a low of $17.25. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $15.70. Year to …

Nov 22, 2023 · Arcus Biosciences stock has received a consensus rating of buy. The average rating score is and is based on 19 buy ratings, 3 hold ratings, and 0 sell ratings. What was the 52-week low for Arcus ... HAYWARD, Calif., December 24, 2022 -- ( BUSINESS WIRE )--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today ...Selection of optimized drug candidates, dosing regimen, pharmacodynamic endpoints, tumor types, and biomarkers for translating inhibition of the adenosine pathway into effective anti-tumor activity. The molecules and their uses are investigational. Arcus has not received approval from any regulatory authority for any use globally, and the ...Arcus Biosciences (RCUS) stock price prediction is 40.382134862897 USD. The Arcus Biosciences stock forecast is 40.382134862897 USD for 2024 November 27, ...Calendar Arcus Biosciences, Inc. Equities. RCUS. US03969F1093. Market Closed - Nyse. Other stock markets.Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently up 3.95% so far this month. During the month of April, Arcus Biosciences Inc’s stock price has reached a high of $19.03 and a low of $16.94. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $15.70. Year to date ...Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 1,450 shares of the Company’s …

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed …

HAYWARD, Calif., February 28, 2023--Arcus Biosciences, Inc. ... Gilead and Arcus entered into a stock purchase agreement under which Gilead made a $200 million equity investment in Arcus.

AstraZeneca and Arcus have a clinical collaboration on Pacific-8 a Phase III study evaluating our anti-TIGIT antibody domvanalimab plus durvalumab (Imfinzi®) for stage 3 non-small cell lung cancer with curative intent. Welcome to investor relations at Arcus Biosciences. We're at the forefront of designing highly-combinable, best-in-class ...Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting ... Arcus Biosciences Stock Forecast. All Analysts Top Analysts Stock Price Forecast. According to 10 stock analysts, the average 12-month stock price forecast for RCUS stock stock is $42.6, which predicts an increase of 165.09%. The lowest target is $23 and the highest is $70. On average, analysts rate RCUS stock stock as a strong buy.Arcus Biosciences Stock Performance. Shares of RCUS opened at $14.05 on Tuesday. Arcus Biosciences, Inc. has a 12-month low of $12.95 and a 12-month high of $36.13. The company’s 50 day simple ...Vir Biotechnology Inc. 9.51. +0.02. +0.21%. Get Arcus Biosciences Inc (RCUS:NYSE) real-time stock quotes, news, price and financial information from CNBC.HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT ...Arcus Biosciences, Inc. Stock price Equities RCUS US03969F1093 Biotechnology & Medical Research Summary Quotes Charts News Ratings Calendar …Mar 9, 2023 · Arcus Biosciences Inc’s (RCUS) price is currently down 8.95% so far this month. During the month of March, Arcus Biosciences Inc’s stock price has reached a high of $18.88 and a low of $16.48. Over the last year, Arcus Biosciences Inc has hit prices as high as $39.75 and as low as $16.74. Year to date, Arcus Biosciences Inc’s stock is ... Responsible for all accounting, audit, financial reporting, treasury, tax, payroll, stock plan administration, contract management and risk management.

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today provided updates on clinical programs and key milestones anticipated in 2022.Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop ...Jul 25, 2023 · Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 21,200 shares of the Company’s common stock at an exercise price ... Instagram:https://instagram. brioni suits pricebest life insurance for young married coupleshow much is carnival stockday trader taxes In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Arcus Biosciences (RCUS – Research Report), with a price target of $51.00.The company’s shares ... best stocks to buy on cashappbest options advisory service Nov 18, 2021 · Shares of Arcus Biosciences ( RCUS 3.94%) jumped by as much as 21% in premarket trading Thursday morning. The biotech's stock is heating up in early morning action today on the news that Gilead ... doorvest reviews Dec 21, 2021 · Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced the closing of Gilead’s option exercises to three programs in Arcus’s clinical-stage portfolio and a new research collaboration between the two companies. On November 17, 2021, Gilead exercised its options to anti-TIGIT molecules domvanalimab and AB308, as well as clinical candidates etrumadenant ... Get Arcus Biosciences Inc (RCUS.N) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments